Ivan Rychlík - Concepedia

Author

Ivan Rychlík

Also Known As

A. Popperlova, Daniela G Alferes, Hormat Rahimzadeh, I RYCHLIK, I Rychlik, I Rychlík, I. RYCHLIK, I. RYCHLÍK, I. Rychlik, I. Rychlík

381

Publications

9.5K

Citations

H-Index

140

Concepts

All Affiliations

Charles University Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry University Medical Center Groningen University of Groningen University of Glasgow

About

Ivan Rychlík is an author at Charles University specializing in medicine, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	40	2.5K
2	Natural Sciences	17	25	715
3	Engineering	3	3	51
4	Health Sciences	3	3	105
5	Public Health	2	2	129

Ivan Rychlík

100

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA Alberto Ortíz, Mario Cozzolino, Danilo Fliser, Nephrology Dialysis Transplantation	2020	363
Carnosine as a Protective Factor in Diabetic Nephropathy Bart Janssen, Daniela Hohenadel, Paul T. Brinkkoetter, Diabetes Metabolic SyndromeProtective FactorKidney ResearchMedicineGenetics	2005	283
Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy James R. Voelker, Paul H. Berg, Matthew J. Sheetz, Journal of the American Society of Nephrology	2016	264
Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides Joost P. Schanstra, Petra Zürbig, Alaa Alkhalaf, Journal of the American Society of Nephrology	2015	248
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial Nete Tofte, Morten Lindhardt, Katarina Adamova, The Lancet Diabetes & Endocrinology UrologyRenal DiseaseRenal FunctionUrinary ProteomicsDiabetes	2020	247
The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000 Ivan Rychlík, Eva Jančová, Vladimı́r Tesař, Nephrology Dialysis Transplantation	2004	245
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial Markus P. Schlaich, M Bellet, Michael A. Weber, The Lancet Molecular PharmacologyHypertensionResistant HypertensionCardiovascular DiseaseAntihypertensive Therapy	2022	206
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Jonathan Barratt, Richard Lafayette, Jens Kristensen, Kidney International	2022	205

Page 1